Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer

BACKGROUND: In patients with newly diagnosed ovarian cancer, bevacizumab and poly(ADP-ribose) polymerase (PARP) inhibitors, alone or in combination, have shown benefit as maintenance treatment following platinum-based chemotherapy. However, no trials have compared a PARP inhibitor plus bevacizumab v...

Descripción completa

Detalles Bibliográficos
Autores principales: Hettle, Robert, McCrea, Charles, Lee, Chee Khoon, Davidson, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488507/
https://www.ncbi.nlm.nih.gov/pubmed/34616492
http://dx.doi.org/10.1177/17588359211049639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488507/
https://www.ncbi.nlm.nih.gov/pubmed/34616492
http://dx.doi.org/10.1177/17588359211049639

Ejemplares similares